cyclo(phe gly)

Arg-Gly-Asp-D-Phe-Val (TFA) has anti-tumor activity and is an inhibitor of integrin αvβ3.

Cyclo(Arg-Gly-Asp-D-Phe-Val) is an integrin αvβ3 inhibitor with antitumor properties, used in acute myeloid leukemia research [1].

Cyclo(Phe-Ala-Gly-Arg-Arg-Arg-Gly-AEEAc) is a potential nonhormonal male contraceptive that functions through the inhibition of GRTH/DDX25 phosphorylation.

Cyclo(RGDfC) TFA (Cyclo(Arg-Gly-Asp-D-Phe-Cys) TFA) is a cyclic pentapeptide, a cyclic RGD polypeptide with high affinity for αvβ3, which is capable of disrupting cellular integrin interactions. Cyclo(RGDfC) TFA inhibits pluripotent gene expression in embryonic stem cells (ESCs) and inhibits tumorigenic potential of mESCs in vivo. Cyclo(RGDfC) TFA inhibits the tumorigenic potential of mESC. Cyclo(RGDfC) TFA can be used for tumor-related studies.

Cyclo(Arg-Ala-Asp-D-Phe-Cys) is a cyclic RAD peptide serving as a positive or negative control for cyclo(Arg-Gly-Asp-D-Phe-Cys). It is utilized in multicolor ultrasound molecular imaging (USMI).